Celsion (CLSN) Downgraded by ValuEngine to Strong Sell
ValuEngine downgraded shares of Celsion (NASDAQ:CLSN) from a sell rating to a strong sell rating in a research note released on Friday morning.
Other research analysts also recently issued reports about the company. Oppenheimer assumed coverage on Celsion in a research note on Tuesday, November 21st. They issued an outperform rating and a $9.00 price target for the company. Zacks Investment Research downgraded Celsion from a buy rating to a hold rating in a research note on Tuesday, October 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $11.90.
Celsion (CLSN) opened at $2.31 on Friday. The firm has a market capitalization of $37.10, a P/E ratio of -0.39 and a beta of 1.81. Celsion has a one year low of $1.24 and a one year high of $7.56.
An institutional investor recently bought a new position in Celsion stock. Sabby Management LLC purchased a new stake in Celsion Co. (NASDAQ:CLSN) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 108,843 shares of the biotechnology company’s stock, valued at approximately $223,000. Sabby Management LLC owned approximately 1.30% of Celsion as of its most recent SEC filing. 4.01% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Celsion (CLSN) Downgraded by ValuEngine to Strong Sell” was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.watchlistnews.com/celsion-clsn-downgraded-by-valuengine-to-strong-sell/1847294.html.
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.